GlaxoSmithKline Pharmaceuticals Limited Asset Resilience Ratio

Latest as of September 2025: 35.83%

GlaxoSmithKline Pharmaceuticals Limited asset resilience ratio. GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has an Asset Resilience Ratio of 35.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GlaxoSmithKline Pharmaceuticals Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Rs13.13 Billion

≈ $142.01 Million USD Cash + Short-term Investments

Total Assets

Rs36.65 Billion

≈ $396.37 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of GlaxoSmithKline Pharmaceuticals Limited (2014–2025)

Asset resilience ratio of GlaxoSmithKline Pharmaceuticals Limited from 2014 to 2025. This chart shows how GlaxoSmithKline Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Read GLAXO total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down GlaxoSmithKline Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GlaxoSmithKline Pharmaceuticals Limited balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs13.13 Billion	35.83%
Total Liquid Assets	Rs13.13 Billion	35.83%

Asset Resilience Insights

Very High Liquidity: GlaxoSmithKline Pharmaceuticals Limited maintains exceptional liquid asset reserves at 35.83% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

GlaxoSmithKline Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio

Compare GlaxoSmithKline Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	0.22%
AstraZeneca PLC NASDAQ:AZN	Drug Manufacturers - General	0.10%
Pfizer Inc SA:PFIZ34	Drug Manufacturers - General	5.33%
Cosmo Pharmaceuticals N.V F:C43	Drug Manufacturers - General	10.92%
Zhejiang Int'L Group Co Ltd SHE:000411	Drug Manufacturers - General	0.00%
Eli Lilly and Company SA:LILY34	Drug Manufacturers - General	6.46%
Dimed S.A. Distribuidora de Medicamentos SA:PNVL3	Drug Manufacturers - General	6.34%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd SHG:600436	Drug Manufacturers - General	17.40%

GlaxoSmithKline Pharmaceuticals Limited Asset Resilience Ratio by Year (2014–2025)

GlaxoSmithKline Pharmaceuticals Limited asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline Pharmaceuticals Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	47.69%	Rs19.59 Billion ≈ $211.89 Million	Rs41.08 Billion ≈ $444.27 Million	-2.71pp
2024-03-31	50.40%	Rs17.93 Billion ≈ $193.87 Million	Rs35.57 Billion ≈ $384.63 Million	+1.73pp
2023-03-31	48.67%	Rs16.19 Billion ≈ $175.11 Million	Rs33.27 Billion ≈ $359.76 Million	-6.25pp
2022-03-31	54.92%	Rs25.45 Billion ≈ $275.20 Million	Rs46.33 Billion ≈ $501.07 Million	+31.41pp
2021-03-31	23.51%	Rs7.32 Billion ≈ $79.16 Million	Rs31.13 Billion ≈ $336.70 Million	-7.01pp
2020-03-31	30.52%	Rs9.57 Billion ≈ $103.50 Million	Rs31.36 Billion ≈ $339.10 Million	+3.70pp
2019-03-31	26.82%	Rs10.49 Billion ≈ $113.45 Million	Rs39.11 Billion ≈ $422.99 Million	+37.26pp
2018-03-31	-10.44%	Rs-4.12 Billion ≈ $-44.56 Million	Rs39.47 Billion ≈ $426.91 Million	-35.98pp
2017-03-31	25.54%	Rs7.67 Billion ≈ $82.97 Million	Rs30.04 Billion ≈ $324.85 Million	-15.56pp
2016-03-31	41.10%	Rs12.52 Billion ≈ $135.41 Million	Rs30.46 Billion ≈ $329.41 Million	-15.96pp
2015-03-31	57.06%	Rs18.40 Billion ≈ $198.98 Million	Rs32.24 Billion ≈ $348.71 Million	+56.74pp
2014-03-31	0.32%	Rs100.03 Million ≈ $1.08 Million	Rs31.30 Billion ≈ $338.45 Million	--

pp = percentage points

About GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General

Market Cap

$4.72 Billion

Rs436.24 Billion INR

Market Cap Rank

#3595 Global

#157 in India

Share Price

Rs2575.10

Change (1 day)

+1.73%

52-Week Range

Rs2103.20 - Rs3106.40

All Time High

Rs3466.20